INTRODUCTION {#SEC1}
============

Autosomal-recessive proximal spinal muscular atrophy (SMA) is a progressive neuromuscular disorder characterized by the selective loss or dysfunction of α-motoneurons in the anterior horn of the spinal cord ([@B1]). With a prevalence of at least 1 in 10 000 live births and a carrier frequency of ∼1 in 40, SMA is amongst the leading genetic cause of infant mortality ([@B2],[@B3]). Based on the time of onset of the disease and its severity, SMA can be divided into five types, with Type 0 and Type I (Werdnig--Hoffman syndrome) being the most severe forms ([@B4]). Patients with severe Type I SMA will usually develop weakness of the proximal muscles of the trunk and body, ultimately leading to muscle atrophy and death from respiratory distress within ∼2 years of age, depending on the choice of palliative care ([@B5]). SMA is caused by disruption of the *survival of motor neuron* (*SMN1*) gene ([@B6]). In humans, a second copy of the *SMN* gene exists but naturally harbours a non-polymorphic C→T transition that interferes with the normal splicing of exon 7, resulting in the expression of a truncated and unstable form of the protein ([@B7]--[@B10]). The low level of full-length functional SMN protein produced in human SMA patients is sufficient to sustain embryonic development and survival of all cells, except lower motoneurons, which seem to have a lower 'tolerance threshold' for SMN levels, a phenomenon which still remains one of foremost questions in the field. SMN exists in cells as part of a stable ∼50S macromolecular complex consisting of at least eight tightly associated components that include Gemins 2--8 and unrip ([@B11]--[@B13]). The best understood function for the core SMN complex is its essential role in promoting the efficiency and specificity of the cytoplasmic assembly of Sm proteins and U snRNAs into small nuclear ribonucleoprotein particles (snRNPs), the core components of the pre-mRNA splicing machinery ([@B11]--[@B14]). Accordingly, a number of studies have now reported lower levels of specific U snRNAs and widespread splicing defects in SMA tissues, including a recently uncovered feedback loop affecting the splicing of *SMN2* exon 7 and misregulation of a subset of U12-dependent introns ([@B15]--[@B24]).

Parallel work also supports additional and distinct roles for SMN in motoneurons, where it localizes to so-called RNA granules along axonal processes and interacts with a number of RNA binding proteins such as FUS/TLS, IMP1/ZBP, TDP-43, hnRNP R/Q, FMRP, KSRP and HuD ([@B25]--[@B36]). RNA granules are responsible for the transport, along microtubules, of specific mRNAs in dendrites and axons, and contribute to the regulation of mRNA stability and local translation at synapses and growth cones, which in turn is crucial for neuronal differentiation, axon outgrowth and synaptic function ([@B37]--[@B39]). Recent studies from our group and others have provided evidence suggesting SMN is somehow required for the proper assembly of RNA granules ([@B25]--[@B27]). Therefore, defects in RNA granules assembly and/or function may account for the various neurite outgrowth and synaptic maturation, stability and functional phenotypes documented in SMA ([@B30],[@B32],[@B40]--[@B49]). It was also demonstrated for the first time recently that local translation of β-actin mRNA was deregulated in motorneurons from a severe mouse model of SMA ([@B50]), although a direct involvement of SMN in this process was not investigated.

In a recent study ([@B51]), we demonstrated that SMN co-fractionates with polyribosomes and represses translation *in vitro*. In this work, we further identified the protein arginine methyltransferase CARM1 as a target that is repressed by SMN at the translational level in motoneuron-derived MN-1 cells. Accordingly, we documented that CARM1 is abnormally up-regulated at the protein level in spinal cord tissue from SMA mice and in severe Type I SMA patient cells. CARM1 is best-known as a transcriptional regulator through its methylation of histones and transcription factors/co-regulators ([@B52]--[@B55]), but has also emerged as a factor able to influence post-transcriptional processes, including alternative pre-mRNA splicing and mRNA stability, through methylation of specific splicing factors and RNA-binding proteins ([@B27],[@B56]--[@B61]). Based on these observations, we used genome-wide exon array technology to identify specific transcriptional and splicing targets of CARM1 in motoneuron-derived MN-1 cells and found that a number of these targets were also misregulated in a SMA cell culture model ([@B51]), strongly suggesting that CARM1 up-regulation contributes to altered gene expression profiles observed in the pathology.

Nonsense-mediated mRNA decay (NMD) is a surveillance mechanism that in addition to preventing production of truncated protein isoforms with potentially noxious consequences for the cell ([@B62]), has also been shown to act on numerous mRNAs thereby contributing to general post-transcriptional gene regulation ([@B63]). In the present study, we report that CARM1 interacts with the essential NMD factor UPF1 in an RNA-dependent fashion and can promote NMD on a generic β-globin pre-mRNA reporter. Additionally, CARM1 was required for interaction of UPF1 with a premature termination codon (PTC)-containing mRNA. We identified a number of well established endogenous NMD targets that were misregulated in the face of modulated CARM1 levels and in SMA conditions. Since there is an aberrant upregulation of CARM1 in SMA, we believe that this (and potentially other mechanisms) induce NMD misregulation of several key mRNAs that could contribute to the SMA pathophysiology.

MATERIALS AND METHODS {#SEC2}
=====================

Cell culture, treatments and transfection experiments {#SEC2-1}
-----------------------------------------------------

Motoneuron-derived Ctrl MN-1 cells, SMN stable knockdown MN-1 cells (shSMN) and CARM1 stable knockdown MN-1 cells (shCARM1) are described previously ([@B27]). Cells were cultured in DMEM (GIBCO) supplemented with 10% fetal bovine serum and maintained in 2 μg/ml of puromycin. For transient transfection, Lipofectamine and Plus Reagents from Invitrogen were used. Cells were harvested for biochemical analyses 48 h after transfection. For the USPL1 depletion experiment, the pGIPZ (OpenBiosystems) control vector and the pGIPZ-shRNA-UPF1 (RHS4430--101031100, V3LHS-352951, OpenBiosystems) were transiently transfected. For cycloheximide (CHX) treatment, cells were treated 4 h with 10 μg/ml. For actinomycin D treatment, cells were incubated for the times indicated in the Figure with 5 μg/ml of the drug. For wortmannin treatment, cells were treated 6 h with 5 μM. The β-Globin WT and MT (NMD) reporters ([@B64]) were a kind gift from Dr Adrian R Krainer (Cold Spring Harbor Laboratory, USA) and the CARM1-WT and CARM1-E266Q plasmids ([@B57]) used for the rescue experiments were a generous gift from Dr Mark T. Bedford (University of Texas M.D. Anderson Cancer Center, USA).

Animals {#SEC2-2}
-------

Spinal cord tissue was harvested from 1 to 3 month old C57 Black 6 SMN+/− mice (obtained from Drs. Alex MacKenzie and Rashmi Kothary), flash frozen in liquid nitrogen and stored at --80°C.

RNA purification, RT-PCR and RT-qPCR {#SEC2-3}
------------------------------------

RNA was extracted by using Trizol (Invitrogen) and treated with DNase I (DNAfree, Ambion). Reverse-transcription (RT) was done by using AMV reverse transcriptase (Promega) and random primers. After completion of the RT reaction, cDNA samples were diluted to a final concentration of 2.5 ng/μl. 5 μl of cDNA samples were used per 25 μl PCR or qPCR reactions. PCR was performed by using GoTaq Flexi DNA Polymerase (Promega) and Quantitative PCR was performed by using iQ SYBR Green Supermix (BioRad) on a Chromo4 Real-Time Detector (BioRad). The relative amounts of cDNA targets in samples were determined on the basis of the threshold cycle for each PCR product (Ct). All semi-quantitative RT- and RT-qPCR primers used in this study and resulting PCR amplicons are shown in Supplementary Table S2.

Co- and RNA-immunoprecipitation experiments {#SEC2-4}
-------------------------------------------

Proteins were extracted from cells collected from 100 mm plates. Cells were first washed in 1× PBS and then incubated in lysis buffer (50 mM Tris-HCl pH 7.5; 150 mM NaCl; 1% NP40; 0.5% Sodium Deoxycholate; and complete protease inhibitor cocktail from Roche Applied Sciences). Immunoprecipitations were done by using Protein A/G PLUS-Agarose beads (sc-2003, Santa Cruz) and 3 μg of specific antibody or 3 μg of control IgG (sc-2027, Santa Cruz). After an overnight incubation, beads were washed four times in lysis buffer. Subsequently, samples were subjected to SDS-PAGE and western blotting analysis. For RNase A treatment (Qiagen, 19101), the cell pellets were first incubated with lysis buffer. Then, RNase A (1 μg/ml) was added to supernatants and the samples were incubated for 1 h at 37°C prior to realize an immunoprecipitation with an UPF1 antibody. RNA-immunoprecipations were performed as described previously ([@B27]). RNA was immunoprecipitated using 4 μg of UPF1 antibody and 4 μg of control rabbit IgG (sc-2027, Santa Cruz).

Immunoblotting {#SEC2-5}
--------------

The following antibodies were used: CARM1 (A300--421A, Bethyl Laboratories); GAPDH (MMS-580S, Covance); β-Actin (sc-47778, Santa Cruz Biotechnology); Tubulin (T6199, Sigma-Aldrich); UPF1 (07--1014, Millipore); UPF2 (D3B10, Cell Signaling); UPF3b (sc-48800, Santa Cruz Biotechnology); Magoh (Ab10686, Abcam); eIF4A3 (Ab32485, Abcam); RBM8a (NB100--55326, Novus Biologicals); Casc3 (LS-C100827, Lifespan Biosciences); Asparagine Synthetase (sc365809, Santa Cruz Biotechnology); Arc (sc15325, Santa Cruz Biotechnology); GADD45a (sc-796, Santa Cruz Biotechnology). Quantitative analyses were done with the ImageJ software.

Statistical analysis {#SEC2-6}
--------------------

For statistical analysis, unpaired *t*-test was used. However, when three or more groups are compared, a one-way ANOVA and post hoc Tukey analysis was used. The minimum α-level of significance was set at 0.05. Data are presented as means ± SEM. In the figures, a single asterisk shows *P* \< 0.05, a double asterisk shows *P* \< 0.01, a triple asterisk shows *P* \< 0.001. Analyses were realized with Graphpad Prism 6 software.

RESULTS {#SEC3}
=======

Aberrant splicing of *USPL1* pre-mRNA is observed in human SMA patients cells {#SEC3-1}
-----------------------------------------------------------------------------

A number of studies have assessed genome-wide gene expression profiles in various models of SMA ([@B15],[@B20],[@B22],[@B65]--[@B66]), but intriguingly, very little overlap has been found between these studies. Amongst the handful of genes identified as misregulated in the pathology is the ubiquitin-specific protease-like 1 (*USPL1*) gene, which was recently found to code for a SUMO isopeptidase shown to localize to Cajal bodies ([@B67]). The *USPL1* pre-mRNA is alternatively spliced within its 5′ end to produce isoforms including or skipping 169 bp cassette-type exon 2. It has been reported that the isoform including exon 2 (E2+) is selectively over-represented in spinal cord tissues from mouse models of severe SMA, relative to the E2- transcript ([@B15],[@B20],[@B68]). To determine if this aberrant splicing event is also observed in SMA patients cells, we assessed the inclusion of exon 2 in primary fibroblasts derived from a severe type I SMA patient. As shown in Figure [1A](#F1){ref-type="fig"}, increased inclusion of *USPL1* exon 2 was observed, indicating for the first time that this alteration is present in human SMA patient cells. We next quantified by RT-qPCR the *USPL1* E2+/E2- ratio in a stable motoneuron MN-1 cell line expressing either a shRNA against SMN (shSMN) or a control shRNA ([@B27],[@B51]). As expected, depletion of SMN resulted in a relative increase in *Uspl1* E2+ mRNA levels relative to E2- isoform, as described in the pathology (Figure [1B](#F1){ref-type="fig"}), indicating that we can recapitulate this molecular defect in a motoneuron-like cell culture model of SMA.

![The ratio of *USPL1* splicing variants is altered in SMA and by CARM1. (**A**) *USPL1* E2+/E2- ratio obtained with the GM00232 primary fibroblasts from a SMA patient was expressed relative to GM08333 primary fibroblasts from an unaffected control. Data are means +/− SEM (*n* = 4). (**B**) Quantification of the *Uspl1* E2+/E2- ratio in the MN-1 pGIPZ CTRL cell line and MN-1 shSMN cell line which stably expressed a shRNA against SMN (shSMN). Results obtained in the shSMN condition were expressed relative to the CTRL cell line. Data are means +/−SEM (*n* = 5). (**C**) CARM1 affects the *USPL1* E2+/E2- ratio. Total RNA was isolated from the MN-1 pGIPZ CTRL cell line and the MN-1 shCARM1 cell line which stably expressed a shRNA against CARM1. *Uspl1* E2+/E2- ratio levels obtained in the shCARM1 cells were expressed relative to CTRL. Data are means +/− SEM (*n* = 6). (**D**) Quantification of the *Uspl1* E2+/E2- ratio in the MN-1 stable cell lines expressing either the pEGFP-C1 empty vector (GFP-C1) or a CARM1-GFP construct. Data obtained in the CARM1-GFP condition were expressed relative to GFP-C1. Data are means +/− SEM (*n* = 6). CARM1 protein levels were assessed in the MN-1 GFP-C1 and MN-1 CARM1-GFP cell lines (upper band, CARM1-GFP). (**E**) MN-1 cell lines were transiently transfected with either a pGIPZ CTRL or shCARM1 plasmid for 24 h. A rescue was performed in the MN-1 shCARM1 cell line by transfecting with either the WT-CARM1 or the CARM1-E266Q mutant expression vectors for an additional 24 h. Protein lysate from transfected MN-1 lines confirm the knockdown and overexpression of CARM1 or the E266Q mutant, normalized to Tubulin. Total RNA was extracted and RT-PCR performed using *Uspl1* primers to amplify both the E2+ and E2- isoforms of the mRNA. 18s RNA was also shown as a loading control. Quantification of the *Uspl1* E2+/E2- ratios in the CARM1 rescue MN-1 cell lines. *Uspl1* mRNA levels are shown as relative to CTRL. Data are means +/− SEM (*n* = 3).](gkv1334fig1){#F1}

CARM1 regulates the relative expression of *Uspl1* alternatively spliced mRNA isoforms {#SEC3-2}
--------------------------------------------------------------------------------------

Our previous work has uncovered that protein levels of the protein arginine methyltransferase CARM1 are up-regulated in spinal cord motor neurons of SMA mouse models and in severe Type I SMA patient cells ([@B51]). This study also identified aberrant gene expression and alternative splicing profiles due to CARM1 up-regulation ([@B51]). To assess if *Uspl1* alternative splicing was also sensitive to CARM1 levels, the E2+/E2- ratio was quantified by RT-qPCR in a motoneuron MN-1 cell line stably expressing an shRNA against CARM1 ([@B27],[@B51]). Strikingly, CARM1 down-regulation resulted in a decrease of the E2+/E2- ratio (Figure [1C](#F1){ref-type="fig"}), thus shifting the ratio opposite to what is observed in the pathology. The E2+/E2- ratio was then quantified in a stable motoneuron MN-1 cell line overexpressing a CARM1-GFP construct. Accordingly, overexpression of CARM1 led to an increased E2+/E2- ratio and thus, mirrors what is seen in the SMA pathology (Figure [1D](#F1){ref-type="fig"}). To insure that the observed changes were not due to non-specific and/or off-target effects, a CARM1 expression rescue experiment was performed, using either wild type (wt) CARM1 or a mutant allele (E266Q) lacking methyltransferase activity ([@B57]) (Figure [1E](#F1){ref-type="fig"}). First, CARM1 levels were knockdown using an shRNA and confirmed by western blot in MN-1 cell lines. RT-PCR was used to confirm the decrease in the *Uspl1* E2+/E2- ratio as previously observed (Figure [1E](#F1){ref-type="fig"}, lanes 1 and 2), which accompanies the decrease in CARM1. As expected, re-introduction of wt CARM1 into the shCARM1 MN-1 cells rescued the *Uspl1* E2+/E2- ratios, returning them towards levels observed in the control condition (Figure [1E](#F1){ref-type="fig"}, lane 3). Intriguingly, re-introduction of the CARM1 E266Q mutant allele rescued E2+/E2- ratios almost as efficiently as the wt allele (Figure [1E](#F1){ref-type="fig"}, lane 4 and quantification from n=3 experiments). Altogether, these results indicate that CARM1 can regulate the expression of *Uspl*1 E2+/E2- ratios, through a mechanism that is seemingly independent of its methyltransferase activity.

Skipping of *Uspl1* alternative exon 2 creates a premature termination codon that elicits NMD {#SEC3-3}
---------------------------------------------------------------------------------------------

Upon closer inspection of the nucleotide sequence surrounding *Uspl1* alternative exon 2, we noted that skipping of exon 2 causes a shift in the coding reading frame resulting in the creation of a premature termination codon (PTC; Figure [2A](#F2){ref-type="fig"}), which, based on its position \>50--55 nt upstream of the exon junction is predicted to elicit the NMD pathway ([@B69],[@B70]). We refer to this transcript as *Uspl1* E2- (Uspl1--006 - ENSMUST00000121416) and the WT transcript which includes exon 2 we denote *Uspl1* E2+ (Uspl1--001 - ENSMUST00000050472). We also observed an additional *Uspl1* isoform containing a 'cryptic' exon upstream of exon 2 which we denoted as exon 1α (Uspl1--002 - ENSMUST00000122160). This isoform did not appear to be regulated by CARM1 and was not included in future analysis and specific qRT-PCR primers were designed to avoid amplification of transcripts containing this exon (Primer list - Supplementary Table S2).

![*Uspl1* is a NMD-regulated target. (**A**) Schematic representation of *Uspl1* E2+ and *Uspl1* E2- transcripts. As depicted in this illustration, the skipping of *Uspl1* exon 2 introduces a Premature Termination Codon (PTC) in exon 2 of the *Uspl1* E2- transcript. (**B**) Impact of the translational inhibitor cycloheximide on the *Uspl1* E2+/E2- ratio. Cells were treated 4 h with cycloheximide (CHX). Then, results obtained in response to CHX were expressed relative to a carrier CTRL. Data are means +/− SEM (*n* = 3). (**C**) UPF1 protein levels were assessed from cell transiently transfected with a control shRNA vector CTRL or a shRNA against UPF1. β-actin was used as a loading control. (**D**) Effect of UPF1 down-regulation on the *Uspl1* E2+/E2- ratio. Data are means +/− SEM (*n* = 3). (**E**) Impact of the SMG-1 inhibitor wortmannin on the *Uspl1* E2+/E2- ratio. Cells were treated 6 h with wortmannin. Subsequently, results obtained in response to wortmannin were expressed relative to DMSO carrier CTRL. Data are means +/− SEM (*n* = 3). (**F**) Quantification of the *Uspl1* E2+ and *Uspl1* E2- mRNA half-lives. MN-1 wt cell lines were treated with actinomycin D (5 μg/ml) for 15, 30 and 60 min. Semi-logarithmic graph shows the decay rate of mRNAs calculated using formula: *(x) = ln(0.5)/b*, where *b* = slope obtained from the trendline formula: *y = ne^−bx^*. Quantification shows the mean +/− SEM (*n* = 6), of *Uspl1* E2+/18S or *Uspl1* E2-/18S. (**G**) Representative RT-PCR gels showing time course of *Uspl1* E2- and *Gapdh* mRNA levels in DMSO carrier CTRL or shCARM1 conditions, treated with actinomycin D. (**H**) Quantification of the *Uspl1* E2- mRNA half-lives in MN-1 pGIPZ CTRL or shCARM1 cell lines. Quantification shows the mean +/− SEM (*n* = 3), of *Uspl1* E2-/*Gapdh*.](gkv1334fig2){#F2}

Since NMD is a process coupled to translation ([@B70]--[@B73]), MN-1 cells were treated with an inhibitor of translation (cycloheximide, CHX) followed by RT-PCR analysis as above to determine the ratio of *Uspl1* isoforms. In response to cycloheximide treatment, the E2+/E2- ratio was decreased relative to carrier treatment (Figure [2B](#F2){ref-type="fig"}), consistent with stabilization of the E2- mRNA in the absence of translation-dependent NMD activity. To further confirm that the E2- transcript is regulated by NMD, a shRNA against UPF1 (Figure [2C](#F2){ref-type="fig"}) was transiently transfected into MN-1 cells. As a result of the down-regulation of the main trans-effector of the NMD process, the *Uspl1* E2+/E2- ratio, as determined using RT-qPCR, was again decreased as compared to an shRNA CTRL (Figure [2D](#F2){ref-type="fig"}). Finally, to ascertain that the *Uspl1* E2- transcript is a NMD target, MN-1 cells were treated with wortmannin, a drug known to inhibit NMD by preventing the phosphorylation of UPF1 by SMG-1 ([@B74],[@B75]). Again, this resulted in a decrease in the E2+/E2- ratio relative to carrier treatment (Figure [2E](#F2){ref-type="fig"}). To further confirm that the E2- transcript is indeed subjected to NMD and regulated at the level of mRNA stability, we determined the half-life of each *Uspl1* alternatively spliced isoform (Figure [2F](#F2){ref-type="fig"}). MN-1 cells were treated with the transcription inhibitor actinomycin D for 15-90 min. Quantification of *Uspl1* E2+ and E2- RNA variants at each time points indicated that the putative E2- NMD transcripts has a considerably shorter half-life of approximately 43 min, relative to the E2+ mRNA at approximately 135 min (Figure [2F](#F2){ref-type="fig"}). Thus, together, these results strongly support the notion that the *Uspl1* E2- isoform is target of the NMD pathway. Since we determined that CARM1 levels influenced the relative ratio of *Uspl1* E2+/E2- isoforms, we next assessed whether this effect was due to an effect on mRNA stability of the E2- mRNA isoform. Thus, the same experiment as in Figure [2F](#F2){ref-type="fig"} was performed using MN1 cells stably transfected with a control shRNA vector or with a shRNA expression plasmid targeting CARM1. Coherent with our findings, the reduction of CARM1 levels resulted in a ∼4.6-fold increase in the *Uspl1* E2- mRNA half-life compared to CTRL conditions (Figure [2G](#F2){ref-type="fig"},[H](#F2){ref-type="fig"}), although these results did not quite reach statistical significance. These results thus suggest that CARM1 can regulate *Uspl1* expression at the level of alternative splicing, and potentially to some extent also at the level of mRNA stability through regulation of the NMD pathway acting on the E2- mRNA isoform.

CARM1 can affect the fate of a generic NMD reporter {#SEC3-4}
---------------------------------------------------

These results prompted us to investigate whether CARM1 has a general impact on NMD. To test this hypothesis, we used a well-characterized NMD reporter system ([@B76]) consisting of the full-length β-globin pre-mRNA as well as a mutant version containing in exon 2, a nonsense mutation which introduces a PTC following splicing (Figure [3A](#F3){ref-type="fig"}). The PTC-containing β-globin mRNA has been thoroughly demonstrated to be a bone fide NMD-regulated target ([@B64],[@B76]). Wild type (WT) or mutant (MT) β-globin reporters were transiently transfected into MN-1 pGIPZ CTRL and MN-1 shCARM1 cell lines (Figure [3B](#F3){ref-type="fig"}, lanes 1--4). In order to quantify the effect of the CARM1 knockdown on the NMD process, levels of the WT and MT reporters were first normalized to their respective pre-mRNA levels (thus accounting for potential differences in transfection efficiency and/or expression levels). Then, the results obtained for the MT reporter were expressed relative to the WT reporter (Figure [3C](#F3){ref-type="fig"}). As shown in Figure [3B](#F3){ref-type="fig"}, the relative abundance of the PTC-containing MT reporter mRNA in the MN-1 pGIPZ CTRL cell line is lower than in its WT counterpart (Figure [3B](#F3){ref-type="fig"} lanes 1--2, and 3C). Remarkably, in the MN-1 CARM1 hypomorph cell line, the amount of the WT minigene is no longer significantly different from the WT (Figure [3B](#F3){ref-type="fig"} lanes 3--4, and 3C), suggesting CARM1 is required for recognition and/or degradation of the PTC-containing mRNA through NMD.

![CARM1 can affect the fate of a generic NMD reporter. (**A**) Schematic representation of the wild-type (WT) β-Globin plasmid and the mutant (MT) β-Globin reporter containing a PTC which elicit degradation by the NMD pathway. (**B**) The WT and MT reporters were transiently transfected either into the MN-1 pGIPZ CTRL or the MN-1 shCARM1 cell line. Furthermore, the WT and MT reporters were also transiently co-transfected with a pcDNA3.1 empty vector, CARM1 or CARM1 E266Q expression vectors into the MN-1 shCARM1 cell line. Representative RT-PCRs of the β-Globin mRNA and β-Globin pre-mRNA are shown. (**C**) After normalization of the β-Globin mRNA to the β-Globin pre-mRNA levels in each condition, the data were expressed relative to the WT. Data are means +/− SEM, (MN-1 CTRL cell line, *n* = 5 and MN-1 shCARM1 cell line, *n* = 3). (**D**) CARM1 protein levels were assessed by western blotting in MN-1 pGIPZ CTRL and MN-1 shCARM1 cell lines. Tubulin was used as loading control.](gkv1334fig3){#F3}

Since CARM1 is a well-known regulator of gene expression through various mechanisms ([@B52]--[@B55],[@B77]--[@B79]), we wanted to rule out the possibility that CARM1 might be mediating its effect on NMD by regulating the expression of one or more of the core NMD factors. Consequently, protein levels of the tetrameric EJC core complex components ([@B80]) as well as the NMD factors UPF1, UPF2 and UPF3b (aka. UPF3X) ([@B81]) were compared in the MN-1 pGIPZ CTRL and MN-1 shCARM1 cell lines (Supplementary Figure S1A,B). Additionally, the mRNA expression patterns measured by RT-qPCR, of the NMD factors *Smg1, Smg6, Smg7* and *Upf2* were also compared in the MN-1 pGIPZ CTRL and shCARM1 cell lines (Supplementary Figure S1C). From these analyses, no significant difference in expression was observed for these key NMD factors upon depletion of CARM1. Altogether, these results strongly suggest that CARM1 can promote NMD, through a mechanism other than through transcriptional regulation of major known NMD factors. To ensure that the observed changes in mRNA levels are not due to off-target effects, a rescue experiment was also performed as above with either wt or E226Q CARM1 alleles. Consistent with our previous observation, re-expression of either WT or mutant CARM1 alleles was able to rescue the efficiency of the NMD process (Figure [3B](#F3){ref-type="fig"} lanes 5--8, and 3C,D). This observation suggests that CARM1 can promote NMD through a mechanism that is somehow independent of its methyltransferase activity.

CARM1 interacts with main NMD effector UPF1 {#SEC3-5}
-------------------------------------------

In order to get some insights into the mechanism through which CARM1 regulates NMD, we assessed its potential interaction with core NMD factors. Since UPF1 is central to the NMD process, an endogenous UPF1 immunoprecipitation was performed in extracts from MN-1 cells and analysed by western blotting for the presence of CARM1. As shown in Figure [4A](#F4){ref-type="fig"}, CARM1 was detected in the endogenous UPF1 immunoprecipitate. Immunoprecipitations with a UPF3 antibody, which detects UPF3b (aka. UPF3X) the first protein to associate with the EJC and recruit UPF2 to the EJC ([@B74]), were also performed, but failed to pull-down CARM1 (Supplementary Figure S2). We also wanted to assess whether CARM1 may interact with UPF1 through a mechanism independent of NMD, like perhaps Staufen1 (Stau1)-mediated decay (SMD). SMD is thought to be a process in which the double-stranded RNA binding protein, Stau1, binds to sites within the 3′ UTR of a subset of transcripts and through interaction with UPF1, has been shown to promote the decay of those transcripts ([@B82]--[@B84]). However, we have not been able to detect any interaction between CARM1 and Stau1, and reducing Stau1 expression using shRNAs did not affect the relative ratio of *Uspl1* E2+/E2- isoforms (data not shown), strongly suggesting that CARM1 is not affecting mRNA fate through an impact on SMD. Because our attempts at demonstrating a potential direct interaction between CARM1 and UPF1 purified from *Escherichia coli* have so far failed (F. Fiorini and H. Le Hir, personal communication), it appears that post-translational modifications might be required for the interaction to occur or, alternatively, that it may be mediated through an intermediate (e.g. protein or RNA). To test the idea that RNA may be necessary for the interaction between UPF1 and CARM1, we next performed co-immunoprecipitations with MN-1 extracts pre-incubated or not with RNase A and assessed the presence of CARM1 in the UPF1 immunoprecipitate by western blotting (Figure [4B](#F4){ref-type="fig"}). Whereas an equivalent amount of UPF1 was immunoprecipitated in both conditions, less CARM1 protein was detected following RNase A treatment, thereby indicating that the interaction is likely mediated via a RNA moiety (Figure [4B](#F4){ref-type="fig"},[C](#F4){ref-type="fig"}).

![CARM1 can be co-immunoprecipitated with UPF1 and the interaction between UPF1 and the β-Globin T39 mutant (MT) decreases with CARM1 knockdown. (**A**) Total cell lysates were prepared from MN-1 cells and subjected to immunoprecipitation with an IgG CTRL or UPF1 antibodies. Immunoprecipitated proteins were then analysed by western blot using antibodies against UPF1 and CARM1. (**B**) UPF1 immunoprecipitation experiments were performed with or without (w/o) pretreatment of the cell lysate with RNase A (1 μg/ml) for 30 min at 37°C. (**C**) Then, the CARM1/UPF1 ratios in response to the RNase A treatments were assessed. Values shown in the bar graph are means +/− SEM (*n* = 3). (**D**) The MT reporter was transiently transfected either into the MN-1 pGIPZ CTRL or the MN-1 shCARM1 cell line. RT-PCR analysis was performed using primers specific for the MT mRNA or pre-mRNA, on total RNA extracted from the CTRL (left panel) or shCARM1 (right panel). (**E**) β-Globin mRNA levels, shown here as percent bound to UPF1, were normalized to overall immunoprecipated UPF1 levels and *Gapdh* mRNA was used as a loading control. Data are means +/− SEM (*n* = 3).](gkv1334fig4){#F4}

UPF1 occupancy on a PTC-containing transcript is reduced in the absence of CARM1 {#SEC3-6}
--------------------------------------------------------------------------------

Since CARM1 interacts with UPF1, and based on our observations indicating it plays more of a scaffolding role (i.e. independent of its methyltransferase activity), we sought to assess whether CARM1 may influence steady-state levels of UPF1 on PTC-containing mRNAs. Using RNA-immunoprecipations, we investigated the effect of CARM1 depletion on the ability of UPF1 to bind to a generic NMD target. MN-1 cells were co-transfected with the PTC-containing β-globin MT reporter pre-mRNA and either a CTRL plasmid or shCARM1. Forty-eight hours after transfection, UPF1 was immunoprecipitated and the amount of the MT reporter mRNAs associated with UPF1 was measured by RT-PCR. After normalization to the amount of UPF1 protein immunoprecipitated in each condition (Figure [4D](#F4){ref-type="fig"}; top panel), the amount of the β-globin MT reporter mRNAs bound to UPF1 was significantly less in cells with reduced CARM1 levels, as compared with CTRL (Figure [4D](#F4){ref-type="fig"},[E](#F4){ref-type="fig"}). It is worth noting that although some level of UPF1 occupancy was also detected on the WT β-globin reporter, consistent with previous reports ([@B85],[@B86]) CARM1 had no impact in this context (Supplementary Figure S3A). Moreover, no detectable occupancy of UPF1 was observed on an unrelated, non PTC-containing pre-mRNA minigene, whether CARM1 was present or not (Supplementary Figure S3B). Together, these experiments strongly suggest that CARM1 promotes NMD, at least in part, by favouring UPF1 association with PTC-containing mRNA transcripts.

CARM1 regulates a diverse subset of known endogenous NMD targets {#SEC3-7}
----------------------------------------------------------------

The impact of CARM1 on synthetic NMD reporters led us to speculate that it may have a broad impact on NMD-regulated transcripts. We therefore assessed the expression levels of several previously validated endogenous NMD targets ([@B87]--[@B94]) in the face of reduced CARM1 levels in MN-1 cells. These transcripts are targets of the NMD machinery because they either: (i) harbour a PTC following inclusion or exclusion of an exon through alternative splicing; (ii) contain an upstream open reading frame (uORF); or (iii) contain introns within their 3′ UTRs ([@B95]). Amongst eight Alternative Splicing-Coupled NMD transcripts that we tested, three (*Sfrs10, hnrnpa2b1* and *Ccar1*) were sensitive to CARM1 levels (Figure [5A](#F5){ref-type="fig"},[B](#F5){ref-type="fig"} and Supplementary Table S1), while for example, the *Nfyb* mRNA was not dependent on CARM1 (Figure [5C](#F5){ref-type="fig"}). As shown by semi-quantitative RT-PCR, the *Sfrs10* isoform containing a PTC upon exon inclusion is increased relative to the skipped isoform in response to CARM1 depletion (Figure [5A](#F5){ref-type="fig"}). However, for *Ccar1*, while the relative ratio of spliced isoform is affected in the face of reduced CARM1 levels (Figure [5B](#F5){ref-type="fig"}), total amount of transcripts appear to stay constant, suggesting that CARM1 likely influences this pre-mRNA at the alternative splicing level rather than through an effect on NMD. In any case, more experiments would be required in order to determine precisely whether CARM1 affects the expression of each of these genes at the level of splicing and/or NMD.

![CARM1 regulates a diverse subset of known NMD targets. (**A**) Total RNA was extracted from MN-1 pGIPZ CTRL and MN-1 shCARM1 cell lines. PCR primer sets were designed to flank the PTC resulting either by exon skipping or exon inclusion. For *Sfrs10*, PTC occurs upon exon inclusion. Values shown in the bar graph are means +/− SEM, *n* = 4. (**B**) For *Ccar1*, PTC is generated upon exon skipping. Values shown in the bar graph are means +/− SEM. (**C**) In the case of *Nfyb* gene, PTC is generated upon exon skipping. After optical quantification of the upper/lower splicing variants ratio, results are expressed relative to the MN-1 pGIPZ CTRL cell line. Values shown in the bar graph are means +/− SEM, *n* = 3 (**D**) A rescue was performed in two of the MN-1 shCARM1 cell lines by then transfecting with either the WT-CARM1 or the CARM1-E266Q mutant expression vectors for an additional 24 h. Protein lysate from transfected MN-1 lines confirm the knockdown and overexpression of CARM1 or the E266Q mutant, normalized to Tubulin. (**E**) Total RNA was extracted and RT-qPCR was used to measure the mRNA levels of targets which were normalized to *18s* RNA levels and presented as relative to pGIPZ CTRL target mRNA levels. Data are means +/− SEM (*n* = 3).](gkv1334fig5){#F5}

We next assessed eight transcripts with distinct NMD-inducing features, that all have been documented elsewhere to be subjected to NMD (Supplementary Table S1), in order to determine whether their steady-state levels was influenced by CARM1. As before, rescue experiments were conducted to ensure that the observed changes were not due to off-target effects. Of the seven transcripts assessed, *Gadd45a* and *Arc*, showed significant dependence on CARM1 levels (Figure [5D](#F5){ref-type="fig"},[E](#F5){ref-type="fig"}). A general trend towards CARM1-sensitivity was also observed for *Asns*, although statistical significance was not quite attained using CARM1 shRNA knock-downs (see below). For *Gadd45a*, both wt and methyltransferase-dead CARM1 alleles were as efficient at rescuing mRNA levels to that of CTRL (Figure [5D](#F5){ref-type="fig"},[E](#F5){ref-type="fig"}). However, for *Arc*, the E266Q mutant did not fully rescue mRNA levels to that of CTRL, suggesting that methyltransferase activity could be involved in the mechanism by which CARM1 regulates this specific target (Figure [5D](#F5){ref-type="fig"},[E](#F5){ref-type="fig"} and see Discussion).

To further and independently confirm that CARM1 is involved in regulating those specific endogenous NMD targets at the level of mRNA stability, we made use of mouse embryonic fibroblasts (MEFs) derived from *Carm1*^−/−^ mice ([@B96]) (Figure [6](#F6){ref-type="fig"}). Using Actinomycin D treatments as described above, we measured the half-lives of the endogenous NMD targets *Arc, Gadd45a* and *Asns* ([@B90],[@B94]), by RT-qPCR in wt and *Carm1*^−/−^ MEFs. As predicted, all three NMD target mRNAs, this time including *Asns*, showed stabilization in *Carm1 ^−/−^* MEFs (Figure [6B](#F6){ref-type="fig"},[C](#F6){ref-type="fig"} and Supplementary Figure S4). Specifically, for *Gadd45a*, the calculated half-life was of ∼3.2 h in wt MEFs, compare with ∼5 h in *Carm1* -/- cells (Figure [6B](#F6){ref-type="fig"}). Interestingly, this was comparable to the level of stabilization observed upon inhibition of NMD using Wortmannin in wt MEFs (see gel in Figure [6B](#F6){ref-type="fig"}). A similar phenomenon was also observed with *Asns*, with the half-life of the mRNA increasing by \> 2-fold between wt and *Carm1 -/-* MEFs (Figure [6C](#F6){ref-type="fig"}), and this difference also being reflected at the protein level (Figure [6A](#F6){ref-type="fig"}). However, for *Arc*, even if an ∼2-fold increase in mRNA steady-state (Figure [5E](#F5){ref-type="fig"}) and protein (Figure [6A](#F6){ref-type="fig"}) levels was seen in CARM1-depleted cells, the measured difference in actual mRNA stability did not quite reach statistical significance (Supplementary Figure S4), suggesting CARM1 may affect this particular target mostly at the level of transcription. Altogether, these experiments strongly suggest that, in addition to its well-known roles in regulating transcription and alternative splicing, CARM1 can also promote degradation of a specific subset of mRNAs through the NMD pathway.

![NMD target stability and protein expression in *Carm1 +/+* and *Carm1 -/-* MEFs. (**A**) Western blotting analysis and quantification shows levels of CARM1, UPF1 and NMD targets ASNS and ARC protein levels in *Carm1 +/+* (wt) and *Carm1 -/-* MEFs. Tubulin was used as loading control. Data are means +/− SEM (*n* = 3). (**B**,**C**) Quantification of NMD transcripts *Gadd45A* and *Asns* mRNA half-lives normalized to *Gapdh*. Semi-logarithmic graph shows the decay rate of mRNAs calculated using formula: *(x) = ln(0.5)/b*, where *b* = slope obtained from the trendline formula: *y = ne^−bx^*. *Carm1 +/+* and *Carm1 -/-* MEFs were pretreated with either a vehicle or Wortmannin (5 μM) and followed by treatment with actinomycin D (5 μg/ml) and RNA extraction at 0, 2, 4, 6 and 8 h. Quantification shows the means +/− SEM (*n* = 3) and data are presented as relative to zero time point.](gkv1334fig6){#F6}

CARM1-dependent NMD targets misregulated in SMA {#SEC3-8}
-----------------------------------------------

Since we previously reported that CARM1 levels are up-regulated in SMA ([@B51]), we reasoned that NMD targets found here to be CARM1-sensitive should be down-regulated in SMA-like settings. We first extended our findings to an *in vivo* setting by investigating the expression levels of the known endogenous NMD targets which we found to be CARM1 sensitive, in *Smn*^+/−^ mice. Mice heterozygous for Smn show ∼50% motor neuron attrition by ∼6 months of age and are used as a model for mild SMA in humans ([@B97]). Western blot analysis confirmed upregulation of CARM1 in these mice at pre-symptomatic time-points, and we observed no significant changes in UPF1 protein levels (Figure [7A](#F7){ref-type="fig"},[B](#F7){ref-type="fig"}). RT-qPCR analysis of CARM1-sensitive NMD targets *Gadd45a, Arc* and *Asns*, revealed a significant decrease in mRNA expression levels in *Smn*^+/−^ mouse spinal cord tissue as compared to wt (Figure [7C](#F7){ref-type="fig"}). These data, in conjunction with the increased CARM1 levels seen in the *Smn*^+/−^ mice and the steady UPF1 levels in both conditions, are consistent with these targets being misregulated in SMA, at least in part, through a CARM1-dependent decay mechanism, although further experiments would be warranted to clearly demonstrate this link. Finally, we observed misregulation of *ARC, ASNS* and *ATF4* (another known endogenous NMD target) mRNAs in two independent type I SMA patients fibroblast cell lines, when compared to a fibroblast line derived from an unaffected carrier (Figure [7D](#F7){ref-type="fig"},[E](#F7){ref-type="fig"}). Interestingly, treatment of SMA fibroblasts with Wortmannin to inhibit the NMD pathway led to an increase in the levels of these mRNAs (Figure [7D](#F7){ref-type="fig"},[E](#F7){ref-type="fig"}), consistent with these mRNAs being misregulated in SMA due to a defect in NMD. Altogether, these results suggest that at least a subset of CARM1-sensitive NMD targets are decreased in SMA-like settings, supporting the notion that the NMD pathway may somehow be exacerbated in SMA.

![Endogenous NMD targets are mis-regulated in *Smn +/−* mice and SMA type I fibroblasts. (**A**) Protein lysate was collected from the spinal cord tissue of wt and *Smn +/−* mice. CARM1, UPF1 and SMN protein levels were assessed by western blotting. (**B**) Quantification of protein levels were gathered by normalizing to tubulin levels. Data are means +/− SEM (*n* = 3) (**C**) Total RNA was extracted from spinal cord tissue of wt and *Smn +/−* mice. RT-qPCR was used to measure the mRNA levels of targets which were normalized to *Gapdh* mRNA levels and presented as relative to wt target mRNA levels. Data are means +/− SEM (*n* = 3). (**D**,**E**) Fibroblast cell lines from two independent human SMA type I patients (GM00232, GM03813) were treated with Wortmannin (5 μM) for 6 h. Untreated fibroblast cell lines from a carrier (GM03815) were used as CTRL. Total RNA was isolated from the cell lines and three non-ASC-NMD target mRNA expression levels were measured by RT-qPCR: *ARC, ASNS* and *ATF4* using GAPDH as a normalization control. Data are means +/− SEM (*ARC, ATF4n* = 6; *ASNSn* = 5).](gkv1334fig7){#F7}

DISCUSSION {#SEC4}
==========

We report in the present study that CARM1 promotes down-regulation of a specific subset of NMD substrates. Specifically, we found that CARM1 is required to elicit NMD on a generic NMD reporter, through a mechanism that is independent of its methyltransferase activity. We also demonstrate that CARM1 interacts with major NMD factor UPF1, in an RNA-dependent fashion, and that occupancy of UPF1 on a PTC-containing transcript is significantly decreased in CARM1-depleted cells. Finally, consistent with the fact that CARM1 is upregulated in SMA-like settings, we provide evidence that the NMD pathway may somehow be exacerbated in SMA.

CARM1 promotes down-regulation of mRNAs with different NMD-inducing features {#SEC4-1}
----------------------------------------------------------------------------

We have initially focussed our efforts on *Uspl1* in the present study and uncovered that an alternatively spliced isoform resulting from the skipping of exon 2 was a target for NMD. This finding was also corroborated by the fact that *Uspl1* was identified in a recent unbiased, genome-wide screen for novel NMD targets ([@B98]). While we clearly demonstrated that reduced levels of CARM1 affected the relative ratio of *Uspl1* alternatively spliced isoforms, our mRNA stability assessments suggested that this effect was likely mediated principally at the splicing level, although we can not rule out some contribution at the level of NMD. We also observed an effect of CARM1 on the relative ratio of spliced isoforms for three other genes, *Sfrs10, HnRNPa2b1* and *Ccar1* (Supplementary Table S1), although additional experiments would be required to determine precisely whether CARM1 affects splicing and/or NMD for those targets. Because it is often more difficult for splicing-coupled NMD targets to discern between an effect on splicing and/or NMD, we next decided to focus on well-established endogenous NMD targets with distinct NMD-inducing features. We documented three such endogenous transcripts (*Gadd45a, Arc* and *Asns*) which are targets of NMD due to features unrelated to alternative splicing (e.g. uORFs or introns in the 3′ UTR), that are CARM1-sensitive. This suggest that CARM1\'s influence on NMD targets is not dependent on the mechanism through which NMD is elicited. Nevertheless, not all previously validated endogenous NMD targets we assayed were CARM1-sensitive (see Supplementary Table S1), suggestive of a significant degree of target specificity for CARM1\'s regulation of NMD targets. For example, we have found that CARM1 did not influence mRNA or protein levels of major NMD factors (Supplementary Figure S1), many of which are known to be regulated through the NMD pathway in a negative feedback regulatory loop involved in establishing and maintain NMD homeostasis ([@B63],[@B99]). There is mounting evidence in the literature that several NMD branches exist ([@B100]--[@B102]), each with distinct substrate specificity features, so it would be interesting to determine whether this may explain CARM1\'s NMD target discrimination. Identification of additional CARM1-dependent NMD targets in future studies, ideally through unbiased genome-wide approaches, should allow to determine the precise mechanism(s) through which CARM1 target specificity is arising.

CARM1 interacts with major NMD factor UPF1 {#SEC4-2}
------------------------------------------

We have observed that CARM1 interacts with UPF1, in an RNA-dependent fashion, using co-immunoprecipitation experiments, with endogenous proteins. However, we have not been able to detect a signal for CARM1 upon UPF3b or UFP2 immunoprecipitations (Supplementary Figure S2 and data not shown, respectively). Nevertheless, both these antibodies were not very efficient at immunoprecipitating their respective target, so we can not rule out at this point that a lack of signal for CARM1 in these experiments could be due to technical issues, like e.g. insufficient sensitivity or masking of an interaction domain by the antibodies. In an attempt to address the functional relevance of the CARM1/UPF1 interaction, we used RIP assays to measure the occupancy of UPF1 on a PTC-containing transcript, and found that occupancy was reduced upon CARM1 depletion by RNA interference. This provides further evidence that CARM1 promotes NMD, and suggest that it may play a scaffolding role at some point along the NMD pathway. Nevertheless, it was recently shown that target discrimination is likely determined by the ATPase-dependent duration of UPF1 occupancy (off-rate) on mRNAs ([@B85]), so it will be interesting to investigate whether CARM1 affects this process. Such a scaffolding role for CARM1 would be consistent with our observation that CARM1\'s methyltransferase activity is dispensable for its function in promoting down-regulation of NMD substrates. This is also in line with the fact that we were unable to detect any methylation mark in UPF1 using mass spectrometry (data not shown). Interestingly, the methyltransferase-DEAD E266Q CARM1 mutant was as efficient as wt CARM1 in rescue experiments, for all targets tested except for *Arc*, which we in fact showed is likely regulated by CARM1 mostly at the level of transcription. There are other documented cases of activity-independent roles for PRMTs. For example, Jayne *et al*. have reported that CARM1 methyltransferase activity was dispensable for the expression of a subset of NF-κB target genes in response to either TNFα or PMA/ionomycin stimuli ([@B103]). In the case of Rmt3, the homolog of human PRMT3 in *Schizosaccharomyces pombe*, Perrault *et al*. ([@B104]) demonstrated that enzymatic inactive mutants of Rmt3 were able to rescue the ribosomal 40S formation defect in Rmt3-null cells. Interestingly, they also observed that an Rps2 mutant in which the methylated arginines were substituted by lysines (which are not substrates for PRMTs but still have a positive charge) was still able to rescue the defects whereas Rmt3 mutants failing to interact with Rps2 did not. Altogether, these data argue that in addition to their enzymatic activity, PRMTs can also have methyltransferase-independent roles in scaffolding and/or stabilization of complexes through protein-protein and protein-RNA interactions. Nevertheless, it is known that transcriptional events can impact on the efficiency of NMD ([@B105]--[@B107]), so considering that CARM1 is a well-known transcriptional and splicing regulator, further investigations will be required in order to determine the precise mechanism by which it can promote NMD.

Potential contribution of misregulated NMD targets to the pathophysiology of SMA? {#SEC4-3}
---------------------------------------------------------------------------------

In the current study we have used the *Smn*^+/−^ mice to confirm our results in an *in vivo* setting that would allow us to assess protein expression profiles at a pre-phenotypic or disease onset time-point. Using this model, we reproduced our previous observation that CARM1 was upregulated (∼60%) in spinal cord tissues, with no significant difference in main NMD mediator UPF1 levels, thus providing an ideal *in vivo* model to validate CARM1-sensitive NMD targets identified in our cell culture models. We were also able to corroborate some of our findings in two SMA Type I patient fibroblast cell lines, importantly showing that treatment with NMD inhibitor Wortmannin was able to restore steady-state expression levels of a subset of NMD substrates found to be misregulated in these cells. However, these experiments were performed with a very limited number of lines and lacked a proper, genetically matched, control to allow for a stringent comparative analysis. It is interesting to note that amongst the NMD targets that we have found to be misregulated in SMA, both *ATF4* and *GADD45a*, are well known mediators of cellular stress response ([@B108],[@B109]). More specifically, for example the ATF4/GADD45a axis was recently shown to contribute to skeletal muscle atrophy ([@B109],[@B110]). Nevertheless, the fact that we observe a decrease in *ATF4* and *GADD45a* levels may seem counter-intuitive, but it will be important to investigate this further in relevant tissues (i.e. motorneurons, skeletal muscles, glial cells) and at various developmental stages in more severe SMA models. Another known NMD target that we have found to be downregulated in SMA, and which might have important implications for the pathophysiology of the disease, is the immediate-early gene *Arc*. It was elegantly shown by Melissa Moore\'s group in 2007 that *Arc* mRNA are subjected to 'translation-dependent decay (TDD)' in dentrites of neuronal cells, as part of the mechanisms involved in maintaining its restricted protein expression at synapses ([@B94]). The Arc protein, through its dynamic expression, is a crucial mediator of homeostatic synaptic scaling of AMPA type glutamate in order to exert minute control over individual synaptic strength and overall cellular excitability ([@B111],[@B112]). Strikingly, the existence of sensory-motor circuitry defects was recently demonstrated in SMA model mice, which among other things involved intrinsic hyperexcitability of SMA motoneurons ([@B47]). This hyperexcitability phenotype is in fact consistent with the reduced *Arc* levels that we have documented in the current study, suggesting misregulated expression of Arc in motoneuron dentrites may contribute, at least in part, to defects in the SMA sensory-motor circuit. Altogether, our results are consistent with the notion that the NMD pathway may somehow be exarcebated in SMA, although obviously, additional experiments, in more relevant models of the disease, will be necessary to clearly establish whether this contributes to SMA pathophysiology.
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